Charco NeurotechLtd has developed the CUE1, a small, non-invasive, wearable therapeutic device for people with Parkinson’s disease. Worn on the sternum, the device delivers two validated neuromodulation therapies at the same time: focused vibrotactile stimulation and ‘cueing’. These improve motor performance and alleviate numerous symptoms, for example countering ‘freezing of gait’ (when people feel their feet are stuck to the ground).
The CUE1’s focused stimulation works with the body’s sensory system to help improve the speed and fluidity of an individual’s movement. Cueing uses regular or rhythmic stimuli to assist a person with Parkinson’s to start and continue movements like walking. Patients who have benefitted from the CUE1 say that their motions become smoother and better coordinated when wearing the device.
Everyone’s Parkinson’s is different, so an accompanying Bluetooth-enabled app (the CUE app) allows an individual to fine-tune the device’s vibration settings. It also provides a symptom tracker plus interactive games to record progress and movement.
Soo-Min (Lucy) Jung is the co-founder and CEO at Charco Neurotech. Lucy joined the Shott Scale Up Accelerator in 2022 and says, “As Charco grows, I would like to enhance my leadership skills in several key areas, including strategic negotiations and dealmaking. The mentorship will also be an important element in my professional development – I will benefit both from the mentor’s advice and their expertise.”
At the end of 2021, Charco raised £7.4 million in a seed investment round. The company will use this to expand its team and continue the release of the CUE1. The funding will also ensure that the production of the device is fully scalable and the manufacturing quality is consistent. The backers of Charco believe that the CUE1 has the ability to greatly enhance the quality of life for people diagnosed with Parkinson’s worldwide.